BioDelivery Sciences Internationa.../ US09060J1060 /
2022-03-22 12:00:00 AM | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
5.5900USD | - | 2.11 mill. Turnover: - |
-Bid Size: - | -Ask Size: - | 5.6000 | 5.5900 |
GlobeNewswire
03-05
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
2022-02-15
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery...
GlobeNewswire
2022-02-14
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages I...
GlobeNewswire
2022-02-14
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences Internatio...
GlobeNewswire
2022-01-20
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
GlobeNewswire
2021-12-20
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alv...
GlobeNewswire
2021-11-01
Coya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chi...
GlobeNewswire
2021-10-20
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
GlobeNewswire
2021-10-05
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer
GlobeNewswire
2021-09-09
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in ...
GlobeNewswire
2021-09-07
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAIN...
GlobeNewswire
2021-09-03
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
GlobeNewswire
2021-08-16
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
GlobeNewswire
2021-08-04
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™...
GlobeNewswire
2021-07-22
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021